Login / Signup

Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.

Melinda A PruisM S PaatsW R R GeurtsHendrikus Jan DubbinkAnne-Marie C Dingemans
Published in: JCO precision oncology (2022)
Keyphrases
  • advanced non small cell lung cancer
  • tyrosine kinase
  • small cell lung cancer
  • epidermal growth factor receptor